Translocation of gold nanoparticles across the lung epithelial tissue barrier: Combining in vitro and in silico methods to substitute in vivo experiments

Particle and Fibre Toxicology

Volumn 12, Issue 1, 2015, Pages

  Bachler, Gerald ^a,b   Losert, Sabrina ^a,c   Umehara, Yuki ^b   von Goetz, Natalie ^a   Rodriguez Lorenzo, Laura ^b   Petri Fink, Alke ^b   Rothen Rutishauser, Barbara ^b   Hungerbuehler, Konrad ^a  

^a ETH ZURICH   (Switzerland)

^b UNIVERSITY OF FRIBOURG   (Switzerland)

^c SWISS FEDERAL LABORATORIES FOR MATERIALS SCIENCE AND TECHNOLOGY   (Switzerland)

Author keywords

3R; A549; Air liquid interface; ALICE; Epithelial cell monolayers; Inhalation exposure; MLE 12; MLE12; PBPK model; PBTK model

Indexed keywords

GOLD NANOPARTICLE; AEROSOL; GOLD DERIVATIVE; METAL NANOPARTICLE;

A549 CELL LINE; AEROSOL; ANIMAL CELL; ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; EXPOSURE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG ALVEOLUS EPITHELIUM; MEMBRANE TRANSPORT; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; TRANSPORT KINETICS; ANIMAL; BIOLOGICAL MODEL; BLOOD; COMPARATIVE STUDY; COMPUTER SIMULATION; EPITHELIUM CELL; INHALATIONAL DRUG ADMINISTRATION; METABOLISM; RESPIRATORY MUCOSA; TISSUE DISTRIBUTION; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

ANIMALIA;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; COMPUTER SIMULATION; EPITHELIAL CELLS; GOLD COMPOUNDS; HUMANS; METAL NANOPARTICLES; MICE; MODELS, BIOLOGICAL; PARTICLE SIZE; RESPIRATORY MUCOSA; TISSUE DISTRIBUTION;

EID: 84933046629     PISSN: None     EISSN: 17438977     Source Type: Journal    
DOI: 10.1186/s12989-015-0090-8     Document Type: Article

References (77)

1. Project on Emerging Nanotechnologies: Consumer Products Inventory. [ http://www.nanotechproject.org/cpi ]
2. Lee J, Mahendra S, Alvarez PJJ. Nanomaterials in the construction industry: a review of their applications and environmental health and safety considerations. ACS Nano. 2010;4:3580-90.
3. Veprek S, Veprek-Heijman MJG. Industrial applications of superhard nanocomposite coatings. Surf Coat Technol. 2008;202:5063-73.
4. Yokel RA, MacPhail RC. Engineered nanomaterials: exposures, hazards, and risk prevention. J Occup Med Toxicol. 2011;6.
5. Nazarenko Y, Han TW, Lioy PJ, Mainelis G. Potential for exposure to engineered nanoparticles from nanotechnology-based consumer spray products. J Expo Sci Environ Epidemiol. 2011;21:515-28.
6. Lorenz C, Hagendorfer H, von Goetz N, Kaegi R, Gehrig R, Ulrich A, et al. Nanosized aerosols from consumer sprays: experimental analysis and exposure modeling for four commercial products. J Nanopart Res. 2011;13:3377-91.
7. Quadros ME, Marr LC. Silver nanoparticles and total aerosols emitted by nanotechnology-related consumer spray products. Environ Sci Technol. 2011;45:10713-9.
8. Gehr P, Schurch S, Berthiaume Y, Hof VI, Geiser M. Particle retention in airways by surfactant. J Aerosol Med. 1990;3:27-43.
9. Schurch S, Gehr P, Hof VI, Geiser M, Green F. Surfactant displaces particles toward the epithelium in airways and alveoli. Respir Physiol. 1990;80:17-32.
10. Frohlich E, Salar-Behzadi S. Toxicological assessment of inhaled nanoparticles: role of in vivo, ex vivo, in vitro, and in silico studies. Int J Mol Sci. 2014;15:4795-822.
11. ICRP. Human respiratory tract model for radiological protection. A report of a task group of the International Commission on Radiological Protection: ICRP publication 66. Ann ICRP. 1994;24:1-482.
12. Brandenberger C, Rothen-Rutishauser B, Muhlfeld C, Schmid O, Ferron GA, Maier KL, et al. Effects and uptake of gold nanoparticles deposited at the air-liquid interface of a human epithelial airway model. Toxicol Appl Pharmacol. 2010;242:56-65.
13. Herzog F, Clift MJD, Piccapietra F, Behra R, Schmid O, Petri-Fink A, et al. Exposure of silver-nanoparticles and silver-ions to lung cells in vitro at the air-liquid interface. Part Fibre Toxicol. 2013;10.
14. Muller L, Riediker M, Wick P, Mohr M, Gehr P, Rothen-Rutishauser B. Oxidative stress and inflammation response after nanoparticle exposure: differences between human lung cell monocultures and an advanced three-dimensional model of the human epithelial airways. J Royal Soc Interface. 2010;7:S27-40.
15. Landsiedel R, Ma-Hock L, Hofmann T, Wiemann M, Strauss V, Treumann S, et al. Application of short-term inhalation studies to assess the inhalation toxicity of nanomaterials. Part Fibre Toxicol. 2014;11.
16. Ma-Hock L, Burkhardt S, Strauss V, Gamer A, Wiench K, van Ravenzwaay B, et al. Development of a short-term inhalation test in the rat using nano-titanium dioxide as a model substance. Inhalation Toxicol. 2009;21:102-18.
17. BAuA. Toxic effects of various modifications of a nanoparticle following inhalation. Dortmund/Berlin/Dresden, Germany: German Federal Institute for Occupational Safety and Health; 2013. Research Project F 2246.
18. Oberdorster G, Ferin J, Lehnert BE. Correlation between particle-size, in-vivo particle persistence, and lung injury. Environ Health Persp. 1994;102:173-9.
19. Choi HS, Ashitate Y, Lee JH, Kim SH, Matsui A, Insin N, et al. Rapid translocation of nanoparticles from the lung airspaces to the body. Nat Biotechnol. 2010;28:1300-3.
20. Kreyling WG, Hirn S, Moller W, Schleh C, Wenk A, Celik G, et al. Air-blood barrier translocation of tracheally instilled gold nanoparticles inversely depends on particle size. ACS Nano. 2014;8:222-33.
21. Semmler-Behnke M, Kreyling WG, Lipka J, Fertsch S, Wenk A, Takenaka S, et al. Biodistribution of 1.4- and 18-nm gold particles in rats. Small. 2008;4:2108-11.
22. Lipka J, Semmler-Behnke M, Sperling RA, Wenk A, Takenaka S, Schleh C, et al. Biodistribution of PEG-modified gold nanoparticles following intratracheal instillation and intravenous injection. Biomaterials. 2010;31:6574-81.
23. Kreyling WG, Semmler M, Erbe F, Mayer P, Takenaka S, Schulz H, et al. Translocation of ultrafine insoluble iridium particles from lung epithelium to extrapulmonary organs is size dependent but very low. J Toxicol Env Heal A. 2002;65:1513-30.
24. Kreyling WG, Semmler-Behnke M, Seitz J, Scymczak W, Wenk A, Mayer P, et al. Size dependence of the translocation of inhaled iridium and carbon nanoparticle aggregates from the lung of rats to the blood and secondary target organs. Inhal Toxicol. 2009;21:55-60.
25. Sadauskas E, Jacobsen NR, Danscher G, Stoltenberg M, Vogel U, Larsen A, et al. Biodistribution of gold nanoparticles in mouse lung following intratracheal instillation. Chem Cent J. 2009;3.
26. Ji JH, Jung JH, Kim SS, Yoon JU, Park JD, Choi BS, et al. Twenty-eight-day inhalation toxicity study of silver nanoparticles in Sprague-Dawley rats. Inhal Toxicol. 2007;19:857-71.
27. Fazlollahi F, Kim YH, Sipos A, Hamm-Alvarez SF, Borok Z, Kim KJ, et al. Nanoparticle translocation across mouse alveolar epithelial cell monolayers: species-specific mechanisms. Nanomed-Nanotechnol. 2013;9:786-94.
28. Yacobi NR, DeMaio L, Xie JS, Hamm-Alvarez SF, Borok Z, Kim KJ, et al. Polystyrene nanoparticle trafficking across alveolar epithelium. Nanomed-Nanotechnol. 2008;4:139-45.
29. Yacobi NR, Malmstadt N, Fazlollahi F, DeMaio L, Marchelletta R, Hamm-Alvarez SF, et al. Mechanisms of alveolar epithelial translocation of a defined population of nanoparticles. Am J Respir Cell Mol Biol. 2010;42:604-14.
30. Schleh C, Holzwarth U, Hirn S, Wenk A, Simonelli F, Schaffler M, et al. Biodistribution of inhaled gold nanoparticles in mice and the influence of surfactant protein D. J Aerosol Med Pulm Drug Deliv. 2013;26:24-30.
31. Choi JY, Ramachandran G, Kandlikar M. The impact of toxicity testing costs on nanomaterial regulation. Environ Sci Technol. 2009;43:3030-4.
32. Lenz AG, Karg E, Lentner B, Dittrich V, Brandenberger C, Rothen-Rutishauser B, et al. A dose-controlled system for air-liquid interface cell exposure and application to zinc oxide nanoparticles. Part Fibre Toxicol. 2009;6.
33. Wikenheiser KA, Vorbroker DK, Rice WR, Clark JC, Bachurski CJ, Oie HK, et al. Production of immortalized distal respiratory epithelial-cell lines from surfactant protein-C simian virus-40 large tumor-antigen transgenic mice. Proc Natl Acad Sci U S A. 1993;90:11029-33.
34. Lieber M, Smith B, Szakal A, Nelsonrees W, Todaro G. Continuous tumor-cell line from a human lung carcinoma with properties of type-II alveolar epithelial cells. Int J Cancer. 1976;17:62-70.
35. Goppert TM, Muller RH. Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: comparison of plasma protein adsorption patterns. J Drug Target. 2005;13:179-87.
36. MacCuspie RI. Colloidal stability of silver nanoparticles in biologically relevant conditions. J Nanopart Res. 2011;13:2893-908.
37. Saptarshi SR, Duschl A, Lopata AL. Interaction of nanoparticles with proteins: relation to bio-reactivity of the nanoparticle. J Nanobiotechnol. 2013;11.
38. Schleh C, Kreyling WG, Lehr CM. Pulmonary surfactant is indispensable in order to simulate the in vivo situation. Part Fibre Toxicol. 2013;10.
39. Bachler G, von Goetz N, Hungerbuhler K. Using physiologically based pharmacokinetic (PBPK) modeling for dietary risk assessment of titanium dioxide (TiO2) nanoparticles. Nanotoxicology. 2015;9:373-80.
40. The European Commission. Commission Recommendation of 18 October 2011 on the definition of nanomaterial (2011/696/EU). Brussels, Off J Eur Union. 2011;54:38-40.
41. Sakagami M. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv Drug Delivery Rev. 2006;58:1030-60.
42. Mahida YR, Makh S, Hyde S, Gray T, Borriello SP. Effect of clostridium difficile toxin a on human intestinal epithelial cells: induction of interleukin 8 production and apoptosis after cell detachment. Gut. 1996;38:337-47.
43. Rothen-Rutishauser BM, Kiama SG, Gehr P. A three-dimensional cellular model of the human respiratory tract to study the interaction with particles. Am J Respir Cell Mol Biol. 2005;32:281-9.
44. Connor EE, Mwamuka J, Gole A, Murphy CJ, Wyatt MD. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small. 2005;1:325-7.
45. Khlebtsov N, Dykman L. Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studies. Chem Soc Rev. 2011;40:1647-71.
46. Boisselier E, Astruc D. Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity. Chem Soc Rev. 2009;38:1759-82.
47. Benetti F, Fedel M, Minati L, Speranza G, Migliaresi C. Gold nanoparticles: role of size and surface chemistry on blood protein adsorption. J Nanopart Res. 2013;15.
48. Albanese A, Walkey CD, Olsen JB, Guo HB, Emili A, Chan WCW. Secreted biomolecules alter the biological identity and cellular interactions of nanoparticles. ACS Nano. 2014;8:5515-26.
49. Foster KA, Oster CG, Mayer MM, Avery ML, Audus KL. Characterization of the A549 cell line as a type II pulmonary epithelial cell model for drug metabolism. Exp Cell Res. 1998;243:359-66.
50. George I, Vranic S, Boland S, Courtois A, Baeza-Squiban A. Development of an in vitro model of human bronchial epithelial barrier to study nanoparticle translocation. Toxicol in Vitro. 2015;29:51-8.
51. Blank F, Rothen-Rutishauser B, Schurch S, Gehr P. An optimized in vitro model of the respiratory tract wall to study particle cell interactions. J Aerosol Med. 2006;19:392-405.
52. Kemp SJ, Thorley AJ, Gorelik J, Seckl MJ, O'Hare MJ, Arcaro A, et al. Immortalisation of human alveolar epithelial cells to investigate nanoparticle uptake. Am J Respir Cell Mol Biol. 2008;39:591-7.
53. Bove PF, Grubb BR, Okada SF, Ribeiro CMP, Rogers TD, Randell SH, et al. Human alveolar type II cells secrete and absorb liquid in response to local nucleotide signaling. J Biol Chem. 2010;285:34939-49.
54. Thompson KE, Korbmacher JP, Hecht E, Hobi N, Wittekindt OH, Dietl P, et al. Fusion-activated cation entry (FACE) via P2X (4) couples surfactant secretion and alveolar fluid transport. FASEB J. 2013;27:1772-83.
55. Hinderliter PM, Minard KR, Orr G, Chrisler WB, Thrall BD, Pounds JG, et al. A computational model of particle sedimentation, diffusion and target cell dosimetry for in vitro toxicity studies. Part Fibre Toxicol. 2010;7.
56. Teeguarden JG, Hinderliter PM, Orr G, Thrall BD, Pounds JG. Particokinetics in vitro: dosimetry considerations for in vitro nanoparticle toxicity assessments. Toxicol Sci. 2007;95:300-12.
57. Brain JD, Knudson DE, Sorokin SP, Davis MA. Pulmonary distribution of particles given by intratracheal instillation or by aerosol inhalation. Environ Res. 1976;11:13-33.
58. Fazlollahi F, Sipos A, Kim YH, Hamm-Alvarez SF, Borok Z, Kim KJ, et al. Translocation of PEGylated quantum dots across rat alveolar epithelial cell monolayers. Int J Nanomedicine. 2011;6:2849-57.
59. Cohen JM, Derk R, Wang LY, Godleski J, Kobzik L, Brain J, et al. Tracking translocation of industrially relevant engineered nanomaterials (ENMs) across alveolar epithelial monolayers in vitro. Nanotoxicology. 2014;8:216-25.
60. Bachler G, von Goetz N, Hungerbuhler K. A physiologically based pharmacokinetic model for ionic silver and silver nanoparticles. Int J Nanomedicine. 2013;8:3365-82.
61. van Furth R, Cohn ZA, Hirsch JG, Humphrey JH, Spector WG, Langevoort HL. The mononuclear phagocyte system: a new classification of macrophages, monocytes, and their precursor cells. Bull World Health Organ. 1972;46:845-52.
62. Kim YS, Kim JS, Cho HS, Rha DS, Kim JM, Park JD, et al. Twenty-eight-day oral toxicity, genotoxicity, and gender-related tissue distribution of silver nanoparticles in Sprague-Dawley rats. Inhal Toxicol. 2008;20:575-83.
63. Lankveld DP, Oomen AG, Krystek P, Neigh A, Troost-de Jong A, Noorlander CW, et al. The kinetics of the tissue distribution of silver nanoparticles of different sizes. Biomaterials. 2010;31:8350-61.
64. Hirn S, Semmler-Behnke M, Schleh C, Wenk A, Lipka J, Schaffler M, et al. Particle size-dependent and surface charge-dependent biodistribution of gold nanoparticles after intravenous administration. Eur J Pharm Biopharm. 2011;77:407-16.
65. Sarin H. Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability. J Angiogenes Res. 2010;2:1-14.
66. Choi HS, Liu W, Misra P, Tanaka E, Zimmer JP, Itty Ipe B, et al. Renal clearance of quantum dots. Nat Biotechnol. 2007;25:1165-70.
67. SUVA. Grenzwerte am Arbeitsplatz 2014 [Occupational limits 2014]. Luzern, Schweiz: Schweizerische Unfallversicherungsanstalt; 2014. Document Number 1903.d (in German).
68. Yong KT, Sahoo Y, Swihart MT, Prasad PN. Synthesis and plasmonic properties of silver and gold nanoshells on polystyrene cores of different size and of gold-silver core-shell nanostructures. Colloid Surface A. 2006;290:89-105.
69. Jana NR, Gearheart L, Murphy CJ. Seed-mediated growth approach for shape-controlled synthesis of spheroidal and rod-like gold nanoparticles using a surfactant template. Adv Mater. 2001;13:1389-93.
70. Grabar KC, Freeman RG, Hommer MB, Natan MJ. Preparation and characterization of Au colloid monolayers. Anal Chem. 1995;67:735-43.
71. Brown KR, Walter DG, Natan MJ. Seeding of colloidal Au nanoparticle solutions. 2. Improved control of particle size and shape. Chem Mater. 2000;12:306-13.
72. Haiss W, Thanh NTK, Aveyard J, Fernig DG. Determination of size and concentration of gold nanoparticles from UV-Vis spectra. Anal Chem. 2007;79:4215-21.
73. Smoluchowski M. Zur Theorie der elektrischen Kataphorese und der Oberflächenleitung [A theory concerning the electric cataphoresis and the surface conduction]. J Phys Theor Appl. 1907;6:659-60 (in German).
74. Koppel DE. Analysis of macromolecular polydispersity in intensity correlation spectroscopy-method of cumulants. J Chem Phys. 1972;57:4814-20.
75. Cozens AL, Yezzi MJ, Kunzelmann K, Ohrui T, Chin L, Eng K, et al. Cftr expression and chloride secretion in polarized immortal human bronchial epithelial-cells. Am J Respir Cell Mol Biol. 1994;10:38-47.
76. Blank F, Rothen-Rutishauser B, Gehr P. Dendritic cells and macrophages form a transepithelial network against foreign particulate antigens. Am J Respir Cell Mol Biol. 2007;36:669-77.
77. Lehmann AD, Daum N, Bur M, Lehr CM, Gehr P, Rothen-Rutishauser BM. An in vitro triple cell co-culture model with primary cells mimicking the human alveolar epithelial barrier. Eur J Pharm Biopharm. 2011;77:398-406.